BR112015013700A2 - composição, sequência nucleotídica, anticorpo sintético, e, uso da composição - Google Patents
composição, sequência nucleotídica, anticorpo sintético, e, uso da composiçãoInfo
- Publication number
- BR112015013700A2 BR112015013700A2 BR112015013700A BR112015013700A BR112015013700A2 BR 112015013700 A2 BR112015013700 A2 BR 112015013700A2 BR 112015013700 A BR112015013700 A BR 112015013700A BR 112015013700 A BR112015013700 A BR 112015013700A BR 112015013700 A2 BR112015013700 A2 BR 112015013700A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- synthetic antibody
- subject
- nucleotide sequence
- antibody
- Prior art date
Links
- 239000002773 nucleotide Substances 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4633—Antibodies or T cell engagers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1 / 1 resumo âmãtodos para gerar um anticorpo sintãtico, para prevenir ou tratar uma doenãa, e para tratar um sujeito de infecãão por um patãgenoâ ã divulgado neste documento uma composiã§ã£o incluindo uma sequãªncia de ã¡cido nucleico recombinante que codifica um anticorpo. tambã©m ã© divulgado neste documento um mã©todo para gerar um anticorpo sintã©tico em um sujeito ao se administrar a composiã§ã£o ao sujeito. a divulgaã§ã£o tambã©m prov㪠um mã©todo para prevenir e/ou tratar a doenã§a em um sujeito usando dita composiã§ã£o e mã©todo de geraã§ã£o.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261737094P | 2012-12-13 | 2012-12-13 | |
US201361881376P | 2013-09-23 | 2013-09-23 | |
US201361896646P | 2013-10-28 | 2013-10-28 | |
PCT/US2013/075137 WO2014093894A2 (en) | 2012-12-13 | 2013-12-13 | Dna antibody constructs and method of using same |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112015013700A2 true BR112015013700A2 (pt) | 2017-11-14 |
BR112015013700A8 BR112015013700A8 (pt) | 2020-02-18 |
Family
ID=50935092
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015013700A BR112015013700A8 (pt) | 2012-12-13 | 2013-12-13 | composição, sequência nucleotídica, anticorpo sintético, e, uso da composição |
BR112016013493-1A BR112016013493B1 (pt) | 2012-12-13 | 2014-12-13 | Molécula de ácido nucleico, composição, e, uso da molécula de ácido nucleico |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016013493-1A BR112016013493B1 (pt) | 2012-12-13 | 2014-12-13 | Molécula de ácido nucleico, composição, e, uso da molécula de ácido nucleico |
Country Status (15)
Country | Link |
---|---|
US (4) | US9994629B2 (pt) |
EP (1) | EP2931318A4 (pt) |
JP (6) | JP6898060B2 (pt) |
KR (4) | KR20230156146A (pt) |
CN (1) | CN104853782A (pt) |
AU (7) | AU2013358944B2 (pt) |
BR (2) | BR112015013700A8 (pt) |
CA (1) | CA2889723A1 (pt) |
EA (1) | EA201591131A1 (pt) |
HK (1) | HK1213481A1 (pt) |
MX (4) | MX2015007575A (pt) |
MY (1) | MY175708A (pt) |
SG (1) | SG10202002718RA (pt) |
WO (1) | WO2014093894A2 (pt) |
ZA (1) | ZA201503583B (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104853782A (zh) * | 2012-12-13 | 2015-08-19 | 宾夕法尼亚大学理事会 | Dna抗体构建体及其使用方法 |
JP7078350B2 (ja) | 2013-10-28 | 2022-05-31 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Dna抗体構築物及びその使用方法 |
CN105829341A (zh) | 2013-12-13 | 2016-08-03 | 宾夕法尼亚大学理事会 | Dna抗体构建体及其使用方法 |
CA2962799A1 (en) * | 2014-10-01 | 2016-04-07 | The Trustees Of The University Of Pennsylvania | Vaccines having an antigen and interleukin-21 as an adjuvant |
KR20170085131A (ko) * | 2014-12-01 | 2017-07-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Dna 항체 작제물 및 그 이용 방법 |
CN116675776A (zh) | 2015-10-25 | 2023-09-01 | 赛诺菲 | 用于预防或治疗hiv感染的三特异性和/或三价结合蛋白 |
WO2017106326A1 (en) * | 2015-12-14 | 2017-06-22 | The Trustees Of The University Of Pennsylvania | Aav-anti pcsk9 antibody constructs and uses thereof |
MX2018011425A (es) * | 2016-03-21 | 2019-09-04 | B Weiner David | Construcciones de anticuerpos de adn y método para utilizarlas. |
HUE063824T2 (hu) | 2016-04-13 | 2024-02-28 | Sanofi Sa | Trispecifikus és/vagy trivalens kötõfehérjék |
KR20230058733A (ko) * | 2016-05-05 | 2023-05-03 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Il-6 및 cd126을 표적으로하는 dna 단일 클론 항체 |
US11896654B2 (en) * | 2016-05-05 | 2024-02-13 | The Trustees Of The University Of Pennsylvania | DNA monoclonal antibodies targeting checkpoint molecules |
CA3023093A1 (en) * | 2016-05-05 | 2017-11-09 | The Trustees Of The University Of Pennysylvania | Dna monoclonal antibodies targeting influenza virus |
AU2017261374B2 (en) * | 2016-05-05 | 2024-06-20 | Inovio Pharmaceuticals, Inc. | DNA antibody constructs for use against pseudomonas aeruginosa |
JP2019533993A (ja) | 2016-09-19 | 2019-11-28 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ジカウイルスに対する新規ワクチンとジカウイルスに対する使用に向けたdna抗体構築物との組み合わせ |
US11286295B2 (en) | 2016-10-20 | 2022-03-29 | Sanofi | Anti-CHIKV monoclonal antibodies directed against the E2 structural protein |
KR20210117359A (ko) * | 2016-11-07 | 2021-09-28 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | 라임병에 사용하기 위한 dna 항체 작제물 |
US11370830B2 (en) | 2017-04-07 | 2022-06-28 | The Rockefeller University | Neutralizing antibodies that bind to the zika virus domain III envelope region |
BR112019024643A2 (pt) * | 2017-05-22 | 2020-06-23 | National Cheng Kung University | Anticorpo contra vírus da dengue, composição farmacêutica compreendendo o mesmo e seus usos |
WO2019067671A1 (en) * | 2017-09-27 | 2019-04-04 | David Weiner | DNA ANTIBODY CONSTRUCTS FOR USE IN CORONAVIRUS RESPIRATORY SYNDROME OF THE MIDDLE EAST |
WO2019152602A1 (en) * | 2018-01-31 | 2019-08-08 | The Wistar Institute Of Anatomy And Biology | Structurally modified flavivirus dmabs |
US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
EP4003421A4 (en) * | 2019-07-31 | 2023-11-08 | The Wistar Institute of Anatomy and Biology | CONSTRUCTIONS OF MULTIVALENT DNA ANTIBODIES AND THEIR USE |
EP4031168A4 (en) | 2019-09-18 | 2023-10-11 | Intergalactic Therapeutics, Inc. | SYNTHETIC DNA VECTORS AND METHODS OF USE |
SE544000C2 (en) * | 2020-03-17 | 2021-10-26 | Xbrane Biopharma Ab | Novel combination of tis sequence, signal peptide sequence and nucleic acid sequence encoding a recombinant protein |
SE544001C2 (en) * | 2020-03-17 | 2021-10-26 | Xbrane Biopharma Ab | Novel combination of tis sequences, signal peptide sequences and nucleic acid sequences encoding heavy and light chains of an antibody |
US20230136960A1 (en) * | 2020-03-19 | 2023-05-04 | Nature's Toolbox, Inc. | Novel MRNA-Based COVID-19 Multi-Valent Vaccine and Methods of Scaled Production of the Same |
EP4255484A1 (en) * | 2020-12-02 | 2023-10-11 | Thomas Jefferson University | Desmoglein 2-directed chimeric antigen receptor (car) constructs and methods of use |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI46572C (fi) * | 1972-04-07 | 1973-04-10 | Stroemberg Oy Ab | Jännitemuuntaja. |
US7276488B2 (en) | 1997-06-04 | 2007-10-02 | Oxford Biomedica (Uk) Limited | Vector system |
US20030039635A1 (en) | 1998-09-30 | 2003-02-27 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
CN1334343A (zh) * | 2000-07-14 | 2002-02-06 | 中国医学科学院肿瘤医院肿瘤研究所 | 抑制肿瘤生长的新抗体、其衍生物及其应用 |
US20070037165A1 (en) | 2000-09-08 | 2007-02-15 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
WO2004013278A2 (en) * | 2002-08-02 | 2004-02-12 | Yuhan Corporation | Expression vectors |
JP4644663B2 (ja) * | 2003-06-03 | 2011-03-02 | セル ジェネシス インコーポレイテッド | ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法 |
CN1480215A (zh) | 2003-07-07 | 2004-03-10 | 叶新新 | Sars病毒抗原抗体复合疫苗及实验动物模型与方法 |
EP1753871B1 (en) | 2004-05-28 | 2015-07-15 | Agensys, Inc. | Antibodies and related molecules that bind to psca proteins |
KR101282396B1 (ko) * | 2004-05-28 | 2013-07-04 | 어젠시스 인코포레이티드 | Psca 단백질에 결합하는 암 진단용 항체 |
EP1765846A4 (en) | 2004-07-13 | 2010-02-17 | Cell Genesys Inc | AAV VECTOR COMPOSITIONS AND ITS USE IN PROCESSES FOR INCREASING IMMUNOGLOBULIN EXPRESSION |
ZA200701234B (en) | 2004-07-22 | 2008-12-31 | Genentech Inc | HER2 antibody composition |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
CN101160324B (zh) | 2005-02-18 | 2013-04-24 | 米德列斯公司 | 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体 |
US20060216722A1 (en) | 2005-03-25 | 2006-09-28 | Christer Betsholtz | Glomerular expression profiling |
AU2006272706A1 (en) | 2005-07-21 | 2007-02-01 | Abbvie Inc. | Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis |
US8865875B2 (en) | 2007-08-22 | 2014-10-21 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions |
CA2598966A1 (en) | 2007-09-07 | 2009-03-07 | Institut Pasteur | Anti-chikungunya monoclonal antibodies and uses thereof |
JP2009171880A (ja) | 2008-01-23 | 2009-08-06 | Yokohama City Univ | アルツハイマー病における次世代遺伝子治療法・免疫治療法の開発 |
DK2262836T3 (da) | 2008-03-14 | 2016-04-04 | Transgene Sa | Antistof mod CSF-1R |
CN107083391A (zh) | 2008-04-04 | 2017-08-22 | 宾夕法尼亚大学托管会 | 屈曲病毒蛋白共有序列、编码该屈曲病毒蛋白共有序列的核酸分子和组合物及其使用方法 |
AU2009305113B2 (en) * | 2008-10-13 | 2015-07-16 | Institute For Research In Biomedicine | Dengue virus neutralizing antibodies and uses thereof |
ES2536996T3 (es) * | 2009-07-06 | 2015-06-01 | F. Hoffmann-La Roche Ag | Anticuerpos biespecíficos de unión a digoxigenina |
WO2011007363A1 (en) | 2009-07-13 | 2011-01-20 | Bharat Biotech International Limited | A composition useful as rotavirus vaccine and a method therefor. |
US20110045534A1 (en) | 2009-08-20 | 2011-02-24 | Cell Signaling Technology, Inc. | Nucleic Acid Cassette For Producing Recombinant Antibodies |
AU2010298025B2 (en) * | 2009-09-25 | 2016-04-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to HIV-1 and their use |
WO2011047146A2 (en) * | 2009-10-14 | 2011-04-21 | Centocor Ortho Biotech Inc. | Methods of affinity maturing antibodies |
US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
WO2012003995A1 (en) * | 2010-07-09 | 2012-01-12 | Cormus Srl | Lipid-conjugated antibodies |
TWI539963B (zh) | 2010-07-09 | 2016-07-01 | 庫賽爾荷蘭公司 | 抗-人類呼吸道融合性病毒(rsv)抗體及其使用方法 |
US8637035B2 (en) | 2010-07-16 | 2014-01-28 | Academia Sinica | Anti-dengue virus antibodies |
EA027315B1 (ru) | 2010-11-12 | 2017-07-31 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Молекула нуклеиновой кислоты и белок для индукции иммунного ответа против антигена рака предстательной железы, плазмида, вектор экспрессии, способ лечения и фармацевтическая композиция |
EP2670443A4 (en) * | 2011-01-31 | 2015-10-14 | Univ Pennsylvania | NUCLEIC ACID MOLECULES ENCODING NEW HERPES ANTIGENS, VACCINE COMPRISING THE SAME, AND METHODS OF USING SAME |
WO2012106578A1 (en) | 2011-02-04 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc) |
BR112013021494B1 (pt) * | 2011-02-22 | 2021-09-08 | California Institute Of Technology | Vetor viral, polinucleotídeo isolado, uso de um vírus adeno-associado (aav) recombinante e método para produzir o mesmo |
CN102199218A (zh) * | 2011-04-29 | 2011-09-28 | 中国人民解放军军事医学科学院基础医学研究所 | 一种抗Her2抗体-白细胞介素2融合蛋白及其用途 |
US9540657B2 (en) | 2012-05-25 | 2017-01-10 | California Institute Of Technology | Expression of secreted and cell-surface polypeptides |
JP7078350B2 (ja) * | 2013-10-28 | 2022-05-31 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Dna抗体構築物及びその使用方法 |
PL2931304T3 (pl) | 2012-12-13 | 2021-11-08 | The Trustees Of The University Of Pennsylvania | Szczepionka wt1 |
CN104853782A (zh) | 2012-12-13 | 2015-08-19 | 宾夕法尼亚大学理事会 | Dna抗体构建体及其使用方法 |
US20140377269A1 (en) | 2012-12-19 | 2014-12-25 | Adimab, Llc | Multivalent antibody analogs, and methods of their preparation and use |
CN105829341A (zh) | 2013-12-13 | 2016-08-03 | 宾夕法尼亚大学理事会 | Dna抗体构建体及其使用方法 |
-
2013
- 2013-12-13 CN CN201380065674.3A patent/CN104853782A/zh active Pending
- 2013-12-13 CA CA2889723A patent/CA2889723A1/en active Pending
- 2013-12-13 KR KR1020237036307A patent/KR20230156146A/ko active Application Filing
- 2013-12-13 JP JP2015548014A patent/JP6898060B2/ja active Active
- 2013-12-13 BR BR112015013700A patent/BR112015013700A8/pt not_active Application Discontinuation
- 2013-12-13 KR KR1020217020972A patent/KR20210088741A/ko not_active IP Right Cessation
- 2013-12-13 KR KR1020157018712A patent/KR20150093834A/ko active Application Filing
- 2013-12-13 MX MX2015007575A patent/MX2015007575A/es unknown
- 2013-12-13 US US14/651,740 patent/US9994629B2/en active Active
- 2013-12-13 EA EA201591131A patent/EA201591131A1/ru unknown
- 2013-12-13 AU AU2013358944A patent/AU2013358944B2/en active Active
- 2013-12-13 EP EP13863143.7A patent/EP2931318A4/en active Pending
- 2013-12-13 WO PCT/US2013/075137 patent/WO2014093894A2/en active Application Filing
-
2014
- 2014-12-13 MY MYPI2016702163A patent/MY175708A/en unknown
- 2014-12-13 KR KR1020167018560A patent/KR102454610B1/ko active IP Right Grant
- 2014-12-13 AU AU2014361811A patent/AU2014361811B2/en active Active
- 2014-12-13 SG SG10202002718RA patent/SG10202002718RA/en unknown
- 2014-12-13 BR BR112016013493-1A patent/BR112016013493B1/pt active IP Right Grant
- 2014-12-13 MX MX2016007722A patent/MX2016007722A/es unknown
-
2015
- 2015-05-21 ZA ZA2015/03583A patent/ZA201503583B/en unknown
- 2015-06-12 MX MX2022016002A patent/MX2022016002A/es unknown
-
2016
- 2016-02-05 HK HK16101459.4A patent/HK1213481A1/zh unknown
- 2016-06-13 MX MX2021015971A patent/MX2021015971A/es unknown
- 2016-11-18 AU AU2016259451A patent/AU2016259451A1/en not_active Abandoned
-
2018
- 2018-04-30 AU AU2018202997A patent/AU2018202997A1/en not_active Abandoned
- 2018-06-12 US US16/005,997 patent/US20180346554A1/en active Pending
- 2018-09-26 US US16/142,457 patent/US11208470B2/en active Active
-
2019
- 2019-03-27 JP JP2019061531A patent/JP2019115355A/ja active Pending
- 2019-04-04 AU AU2019202343A patent/AU2019202343B2/en active Active
-
2020
- 2020-03-02 JP JP2020035240A patent/JP2020108381A/ja active Pending
- 2020-03-13 AU AU2020201853A patent/AU2020201853B2/en active Active
-
2021
- 2021-02-04 JP JP2021016537A patent/JP2021087433A/ja not_active Withdrawn
- 2021-06-03 AU AU2021203643A patent/AU2021203643A1/en not_active Abandoned
- 2021-12-17 US US17/554,642 patent/US20220112273A1/en not_active Abandoned
-
2023
- 2023-03-15 JP JP2023040876A patent/JP2023080085A/ja active Pending
- 2023-06-30 JP JP2023108341A patent/JP2023138998A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015013700A8 (pt) | composição, sequência nucleotídica, anticorpo sintético, e, uso da composição | |
BR112016025009A2 (pt) | anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície | |
BR112018000601A2 (pt) | moléculas de anticorpo que se ligam ao cd22 | |
BR112017011556A2 (pt) | métodos para gerar um anticorpo sintético, prevenir ou tratar uma doença, tratar um sujeito de infecção por um patógeno e um sujeito com câncer, produto, molécula de ácido nucleico, e, composição. | |
CL2018000107A1 (es) | Moléculas de anticuerpo que se unen a cd79 | |
BR112017022845A2 (pt) | neoepítopos de câncer | |
BRPI0905733B8 (pt) | composição, formulação farmacêutica, método para a produção de uma composição farmacêutica e uso de uma formulação farmacêutica | |
BR112015027315A2 (pt) | melhorias nos ou relativas aos compostos orgânicos | |
BR112014026740A2 (pt) | anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
BR112015007184A2 (pt) | combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer | |
AR088676A1 (es) | Composiciones para tratar superficies incluyendo sales protectoras | |
BR112012019098B8 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica e usos de um anticorpo, de uma composição farmacêutica e de uma combinação farmacêutica | |
BR112016001114A2 (pt) | membros da família tnf direcionados modificados | |
ECSP10010548A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
BR112013032717A2 (pt) | coagonistas do receptor de glucagon/glp-1 | |
WO2015089492A3 (en) | Dna antibody constructs and method of using same | |
BR112012018951B8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
BR112014024269A8 (pt) | Anticorpo ou um fragmento de ligação a antígeno do anticorpo, fragmento de ligação a antígeno do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento de ligação a antígeno, uso de uma composição, vetor, célula hospedeira transformada, e, método para produzir um anticorpo | |
BRPI0919236A8 (pt) | Terapêutica e vacinas de combinação de gas | |
BR112012009432A8 (pt) | Anticorpo anti-hsv e composição farmacêutica que o compreende | |
BR112018072716A2 (pt) | molécula de ácido nucleico, composição, e, métodos para tratar uma doença e para prevenir ou tratar a formação de um biofilme. | |
BR112012026707A2 (pt) | uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado | |
BR112015022825A2 (pt) | métodos de diagnóstico, seleção e tratamento de doenças e condições causadas por ou associadas a metanógenos | |
BR112015012081A2 (pt) | tratamento de café solúvel | |
BR112015023214A8 (pt) | composto, composição farmacêutica, e, uso de um composto ou composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06V | Preliminary requirement: patent application procedure suspended [chapter 6.22 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |